considered and approved un-audited Financial Results of the Company for the quarter and half year ended on September 30, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts less than Nifty Microcap 250 and 0.5 pts less than its Commodity Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Archit Organosys reported Q2 FY26 revenue from operations of Rs. 3,285.99 lakhs, up from Rs. 2,954.05 lakhs in Q2 FY25. Half-year revenue grew to Rs. 6,605.55 lakhs versus Rs. 5,654.49 lakhs in H1 FY25, an increase of about 17%. Net profit for Q2 came in at Rs. 153.92 lakhs (vs Rs. 101.61 lakhs a year ago, up ~51%), while H1 profit jumped to Rs. 357.51 lakhs from Rs. 202.15 lakhs, a ~77% rise. Operating margin expanded notably, with EBITDA proxy (PBT + depreciation + finance cost) margin rising from roughly 12.4% to 14.1% on a half-year basis, helped by lower employee costs and contained finance expenses. Statutory auditor G.K. Co. issued an unqualified limited review report with no qualifications or emphasis of matter, and there were no exceptional items in the period.
Strong year-on-year profit growth and margin expansion, combined with a clean auditor review and no exceptional items, are positive signals for shareholders and could support a constructive short-term stock reaction.